News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Devgen NV Drug Candidates May Promise Breakthrough In The Treatment Of Rheumatoid Arthritis And Other Inflammatory Diseases
August 24, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Devgen (Euronext Brussels: DEVG) announced today that, following encouraging results from studies in animals, one of its preclinical programs may show promise for the treatment of inflammatory diseases.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong
Psychedelics
Compass’ Psychedelic Shows Durability ‘In-Spades’ as Path to FDA Clears
February 17, 2026
·
3 min read
·
Heather McKenzie
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
February 17, 2026
·
2 min read
·
Tristan Manalac
Podcast
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
February 17, 2026
·
1 min read
·
Jef Akst
